-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eli Lilly and Company announced that its investigational IL-13 inhibitor, lebrikizumab, as a monotherapy, has achieved positive results in a pivotal Phase 3 clinical trial in patients with moderate-to-severe atopic dermatitis
Atopic dermatitis is a chronic inflammatory skin disease caused by skin barrier dysfunction and dysregulated immune response
Lebrikizumab is an innovative monoclonal antibody drug that binds IL-13 with high affinity and specificity, thereby preventing the formation of the IL-13Rα1/IL-4Rα complex and inhibiting the receptor complex-mediated signaling pathway
▲Mechanism of action of Lebrikizumab and other antibody therapies targeting IL-4 and IL-13 signaling pathways (Image source: Reference [2])
In the study, called ADvocate 1, 43% of patients treated with lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared with 13% of patients treated with placebo
In the ADvocate 2 study, 33% of patients taking lebrikizumab achieved clear or almost clear skin at 16 weeks, compared with 11% of the placebo group
"Patients' experiences battling autoimmune diseases drive us at Lilly to pursue innovative science and meaningful treatments that make their lives better," said Dr.
References:
[1] Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies.
[2] Moyle et al.
